Crabel Capital Management LLC Makes New $273,000 Investment in Merck & Co., Inc. $MRK

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Crabel Capital Management LLC bought a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,040 shares of the company's stock, valued at approximately $273,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in MRK. Barnes Dennig Private Wealth Management LLC bought a new stake in Merck & Co., Inc. in the first quarter valued at $27,000. Spurstone Advisory Services LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $37,000. MorganRosel Wealth Management LLC bought a new stake in Merck & Co., Inc. in the first quarter valued at $36,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $44,000. Finally, Minot DeBlois Advisors LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $45,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Up 1.3%

Shares of MRK traded up $1.1030 during trading hours on Friday, hitting $87.1830. The company had a trading volume of 11,973,348 shares, compared to its average volume of 15,391,381. The firm has a fifty day moving average price of $81.53 and a 200-day moving average price of $83.14. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a market capitalization of $217.76 billion, a price-to-earnings ratio of 13.43, a P/E/G ratio of 0.89 and a beta of 0.38. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $120.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be given a $0.81 dividend. This represents a $3.24 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend is Monday, September 15th. Merck & Co., Inc.'s payout ratio is currently 49.92%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MRK. Wells Fargo & Company cut their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 30th. Citigroup reiterated a "neutral" rating and issued a $84.00 price target (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Wall Street Zen cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a report on Friday, April 25th. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Finally, Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of "Hold" and an average price target of $107.44.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.